Scynexis INC (NASDAQ:SCYX) said Chief Executive Officer David Angulo Gonzalez acquired 108,695 shares of common stock at a price of $0.92 per share on April 1, 2026, in a private placement tied to a Securities Purchase Agreement. The transaction, valued at about $100,000, also included warrants granting the right to purchase an additional 108,695 shares under the same terms.
The combined purchase price for each share and its accompanying warrant was $0.92. At the time of the filing, Scynexis stock was trading at $0.89 and had posted a 40% year-to-date return.
Following the private placement, Angulo Gonzalez directly holds 1,357,126 shares of Scynexis common stock. That total incorporates 4,000 shares he acquired through the company’s Employee Stock Purchase Plan on March 5, 2026. The warrants issued in the private placement are subject to stockholder approval before they can be exercised and carry an expiration that is either five years from the issue date or 30 days after the release of clinical study data, whichever comes first.
The share purchase by the CEO takes place against a backdrop of corporate financing and clinical activity. Scynexis has announced a private placement financing expected to raise approximately $40 million in gross proceeds through the issuance of shares and warrants, with a closing anticipated around April 1, 2026.
On the clinical front, Scynexis has dosed the first participants in a Phase 1 trial of an intravenous formulation of SCY-247. The trial is intended to study SCY-247 as a treatment for invasive candidiasis and as a prophylactic therapy for invasive fungal disease, with results expected in 2026. The U.S. Food and Drug Administration has granted SCY-247 Fast Track and Qualified Infectious Disease Product (QIDP) designations, which the company notes provide benefits including at least 10 years of market exclusivity and eligibility for accelerated approval.
Analysts continue to model upside potential for Scynexis, with price targets cited in the range of $3 to $4 per share. Separately, Brookline Capital Markets adjusted its target from $4.00 to $3.42 while maintaining a Buy rating, citing progress on the re-launch of BREXAFEMME in partnership with GSK and development progress for SCY-24. Additional subscription-based research tools referenced in filings indicate InvestingPro subscribers have access to 10 extra ProTips and detailed financial metrics for SCYX.
Important items tied to the recent insider transaction include the conditional nature of the warrants - exercisable only upon stockholder approval - and their expiry linked to either a five-year term or a 30-day window following the release of clinical study data. The private placement financing, targeted to raise approximately $40 million, and the timing of clinical readouts expected in 2026 remain focal points for investors and stakeholders.
Summary
Scynexis CEO David Angulo Gonzalez bought 108,695 shares at $0.92 per unit on April 1, 2026, as part of a private placement that included equal-numbered warrants. The company is pursuing a private placement to raise about $40 million, has initiated a Phase 1 IV trial of SCY-247 with readouts expected in 2026, and holds FDA Fast Track and QIDP designations for SCY-247. Analysts’ price targets range from $3 to $4, and Brookline Capital Markets revised its target to $3.42 while keeping a Buy rating.
Key points
- CEO purchase: David Angulo Gonzalez acquired 108,695 shares at $0.92 and received matching warrants on April 1, 2026; post-transaction direct ownership stands at 1,357,126 shares - impacts corporate governance and insider signaling.
- Financing and capital structure: A private placement expected to raise approximately $40 million in gross proceeds involves issuance of shares and warrants, with closing anticipated around April 1, 2026 - impacts equity financing and investor dilution dynamics in the biotech sector.
- Clinical and regulatory progress: SCY-247 has Fast Track and QIDP designations and the first participants have been dosed in a Phase 1 IV trial, with results expected in 2026 - affects clinical development timelines and potential regulatory pathways.
Risks and uncertainties
- Warrant exercise conditions - The warrants granted in the private placement require stockholder approval before exercise, creating uncertainty about future dilution and timing - relevant to equity holders and the broader market for the company’s stock.
- Clinical readout timing and outcome - Trial results for the Phase 1 IV study of SCY-247 are expected in 2026; the timing and content of those data remain uncertain and will affect regulatory and commercial prospects in the infectious disease sector.
- Financing completion - The private placement is anticipated to close around April 1, 2026 and is expected to raise about $40 million in gross proceeds; execution risk around the closing could affect near-term liquidity and funding for development programs.